Add to ORKGBackground: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents. Case presentation: A novel regimen consisting of bortezomib, doxorubicin, and dexamethasone is currently under active evaluation for the treatment of multiple myeloma. We employed this combination as front-line chemoinduction therapy for a case of primary PCL. Conclusion: Complete remission was achieved with rapid normalization of hematologic parameters. The combination of bortezomib, doxorubicin and dexamethasone demonstrates promise in the treatment of PCL. Background Plasma cell leukemia (PCL) is a rare but aggressive fo...
Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disea...
Primary plasma cell leukemia (pPCL) is an uncommon disease. IgM multiple myeloma (MM) is an infreque...
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, characterized by the prese...
Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plas...
Plasma cell leukemia represents the most aggressive form of plasma cell dyscrasia. We report a 67-ye...
BACKGROUND: The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown ...
Bortezomib (Velcade) is currently approved in USA and EU for the treatment of resistant/relapsed mul...
International audiencePURPOSE: Primary plasma cell leukemia (pPCL) is a rare and aggressive malignan...
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezo...
Primary plasma cell leukemia (PPCL) is an aggressive and rare variant of multiple myeloma (MM), char...
The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In ver...
Plasma cell leukemia (PCL) is a rare and aggressive variant of plasma cell dyscrasias that can occur...
Primary plasma cell leukemia (PPCL) is an aggressive and rare variant of multiple myeloma (MM), char...
Plasma cell leukemia (PCL) is a rare hematologic malignancy with aggressive clinical and biologic fe...
Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder characterized by monoclonal prolif...
Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disea...
Primary plasma cell leukemia (pPCL) is an uncommon disease. IgM multiple myeloma (MM) is an infreque...
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, characterized by the prese...
Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plas...
Plasma cell leukemia represents the most aggressive form of plasma cell dyscrasia. We report a 67-ye...
BACKGROUND: The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown ...
Bortezomib (Velcade) is currently approved in USA and EU for the treatment of resistant/relapsed mul...
International audiencePURPOSE: Primary plasma cell leukemia (pPCL) is a rare and aggressive malignan...
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezo...
Primary plasma cell leukemia (PPCL) is an aggressive and rare variant of multiple myeloma (MM), char...
The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In ver...
Plasma cell leukemia (PCL) is a rare and aggressive variant of plasma cell dyscrasias that can occur...
Primary plasma cell leukemia (PPCL) is an aggressive and rare variant of multiple myeloma (MM), char...
Plasma cell leukemia (PCL) is a rare hematologic malignancy with aggressive clinical and biologic fe...
Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder characterized by monoclonal prolif...
Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disea...
Primary plasma cell leukemia (pPCL) is an uncommon disease. IgM multiple myeloma (MM) is an infreque...
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, characterized by the prese...